To conclude, in the background of continued strategic investment due to the striking potential for patients, the 177Lu-PSMA (r)evolution in cancer care must happen and will happen, but key stakeholders must closely collaborate to ensure that HCSs can allow timely and equitable access to treatment. The gene discussed is FOLH1; the disease is cancer.